Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Strong growth both organic and through acquisitions
AddLife's Interim Report for Q2 2021 is now available online at the company website. The Interim Report can be downloaded in pdf version.
Visit reports-en.add.life/delarsrapport-q2-2021
1 APRIL - 30 JUNE 2021 (3 MONTHS)
- Net sales increased by 82 percent to SEK 2,276m (1,248), of which organic growth amounted to 22 percent and acquired growth amounted to 63 percent.
- EBITA increased by 83 percent to SEK 332m (181), corresponding to an EBITA-margin of 14.6 percent (14.5). Transaction costs and stamp duty of SEK 53m has been charged to the result.
- Profit after tax increased by 49 percent to SEK 178m (120).
- Earnings per share amounted to SEK 1.47 (1.07).
- Cash flow from operating activities amounted to SEK 200m (128).
- Two acquisitions were completed during the quarter, Vision Ophthalmology Group and Helathcare 21. The acquisitions are expected to add annual net sales of SEK 2,400m and EBITA of approximately SEK 310m. The acquisitions have been financed through new credits, new share issue of Class B shares and existing shares held in treasury.
1 JANUARY - 30 JUNE 2021 (6 MONTHS)
- Net sales increased by 74 percent to SEK 4,012m (2,301), of which organic growth amounted to 37 percent and acquired growth amounted to 42 percent.
- EBITA increased by 129 percent to SEK 658m (287), corresponding to an EBITA-margin of 16.4 percent (12.5).
- Profit after tax increased by 133 percent to SEK 404m (174).
- Earnings per share amounted to SEK 3.46 (1.55). Earnings per share for the last 12 months amounted to SEK 6.55 (4.63).
- Cash flow from operating activities amounted to SEK 384m (208).
- The equity ratio was 38 percent (46).
- Return on working capital (P/WC) amounted to 115 percent (122).
Stockholm, 15 July 2021
AddLife AB (publ)
For more information, contact;
Kristina Willgård, CEO, kristina.willgard@add.life,+46 70 510 12 23
Martin Almgren, CFO, martin.almgren@add.life,+46 70 228 15 45
www.add.life
Teleconference
Investors. analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. It will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.
The teleconference will be at 10 a.m. on 15 July 2021
If you wish to participate via teleconference, please follow this link>> (https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZmRiNGUxNjAtODJjOS00NTNhLTk1YzUtZDQ2MzdiYzRlZTk3%40thread.v2/0?context=%7b%22Tid%22%3a%2220971130-9feb-4ac0-96f1-e7fbd0d840e4%22%2c%22Oid%22%3a%22f0c4cdd5-3797-4b6d-947a-2bfc2b19c038%22%7d)
Or call in (only sound) +46 8 505 376 58 Conferens-ID: 321 695 644#
The presentation is also available on AddLife YouTube >> (https://www.youtube.com/channel/UC_YiKbKavYICoTU37Y0C8pg)
AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 1,800 employees in some 70 operating subsidiaries. The Group currently has net sales of around SEK 7 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 15 July 2021 at 07:45 a.m. CET.